Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its pr…
| Periodo | 2026-10 | 2023-07 | 2022-10 | 2022-07 |
|---|---|---|---|---|
| Real | — | $28.76 | $20.03 | $33.97 |
| Estimado | — | $18.62 | $67.54 | $59.27 |
| Sorpresa | — | +54.5% | -70.3% | -42.7% |
| Métrica | TAK | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 65.5% | 57.4% | +8.1% |
| Operating Margin | 7.5% | -34.4% | +41.9% |
| Net Margin | 2.4% | -32.5% | +34.8% |
| FCF Margin | 18.7% | -12.6% | +31.3% |
| ROE | 1.6% | -39.2% | +40.7% |
| ROA | 0.8% | -30.9% | +31.7% |
| Current Ratio | 1.01 | 2.73 | -1.72 |
| Debt / Equity | 0.57 | 0.28 | +0.29 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 0.8% | — |
| ✓Flujo de caja operativo positivo | ¥1.06T | ¥716.3B |
| ✗Rentabilidad sobre activos al alza | 0.8% | 1.0% |
| ✓Caja operativa/activos supera al ROA | 7.4% | ROA 0.8% |
| ✓Menos deuda a largo plazo | 27.8% | 29.6% |
| ✗Mejor liquidez (ratio corriente) | 1.01 | 1.11 |
| ✗Sin aumentar el nº de acciones | 1,605M | 1,580M |
| ✗Margen bruto al alza | 65.5% | 66.5% |
| ✓Rotación de activos al alza | 0.32 | 0.28 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 18.7% |
| ✗ROCE > 10 % | 2.9% |
| ✓Ventas > 5 %/año (3 años) | 8.7% |
| ✗Deuda neta/EBITDA < 3x | 3.7x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 20.3% |
TAKEDA PHARMACEUTICAL CO LTD cotiza a 19.67 USD y tiene una capitalización bursátil de $62.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud